NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $6.22 -0.06 (-0.96%) Closing price 04:00 PM EasternExtended Trading$6.23 +0.01 (+0.16%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PHAT alerts:Sign Up Key Stats Today's Range$5.71▼$7.0050-Day Range$5.74▼$9.5752-Week Range$5.01▼$18.31Volume3.84 million shsAverage Volume1.29 million shsMarket Capitalization$503.20 millionP/E RatioN/ADividend YieldN/APrice Target$20.11Consensus RatingModerate Buy Company Overview Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s principal product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress stomach acid through a mechanism distinct from traditional proton pump inhibitors. In the United States, Voquezna is approved for the treatment of Helicobacter pylori infection in combination with antibiotics and for certain forms of gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD. Phathom markets the product in multiple formulations, including combination regimens intended for H. pylori eradication. Phathom was founded to advance vonoprazan-based therapies for acid-related gastrointestinal conditions and has focused its commercial activities primarily on the U.S. market. Vonoprazan was originally developed outside the United States, and Phathom obtained rights to develop and commercialize it in its territory. The company is led by President and Chief Executive Officer Terrie Curran.AI Generated. May Contain Errors. Read More Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScorePHAT MarketRank™: 3.289439710815 of 5 starsPhathom Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 318th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPhathom Pharmaceuticals has a consensus price target of $20.11, representing about 223.3% upside from its current price of $6.22.Amount of Analyst CoveragePhathom Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($0.27) to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.34% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 6.93.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 3.21%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest3 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders9.33% of the stock of Phathom Pharmaceuticals is held by insiders.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAT Stock News HeadlinesPhathom (PHAT) Q3 2026 Earnings Call Transcript2 hours ago | finance.yahoo.comPhathom Pharmaceuticals, Inc. (PHAT) Q3 2026 Earnings Call TranscriptOctober 29 at 2:00 PM | seekingalpha.comNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.October 29 at 1:00 AM | Porter & Company (Ad)Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateOctober 29 at 7:00 AM | globenewswire.comFDA establishes public docket FDA-2026-N-13038 following challenge to VOQUEZNA exclusivityOctober 26 at 7:37 AM | msn.comPhathom Pharmaceuticals Announces FDA Public Docket on VOQUEZNA NCE Exclusivity Amid ANDA LitigationOctober 26 at 4:11 AM | quiverquant.comQPhathom Pharmaceuticals Provides Update on FDA LitigationOctober 26 at 4:00 AM | globenewswire.comPhathom Pharmaceuticals, Inc. announces lawsuit challenging VOQUEZNA exclusivity through May 3, 2032October 23, 2026 | msn.comSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $16.59 at the start of the year. Since then, PHAT shares have decreased by 62.5% and is now trading at $6.22. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its earnings results on Thursday, October, 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.15. The firm had revenue of $84.72 million for the quarter, compared to analysts' expectations of $84.82 million. Read the conference call transcript. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $182 million in an initial public offering on Friday, October 25th 2019. The company issued 9,563,157 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Top institutional shareholders of Phathom Pharmaceuticals include Profund Advisors LLC (0.15%), China Universal Asset Management Co. Ltd., Mirae Asset Global Investments Co. Ltd. (0.01%) and State of Alaska Department of Revenue. Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh, Molly Henderson, James N Topper, Frank Karbe and Robert Charles Breedlove. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include NVIDIA (NVDA), Plug Power (PLUG), Tesla (TSLA), Palantir Technologies (PLTR), Ardelyx (ARDX), Definium Therapeutics (DFTX) and Cassava Sciences (FLNA). Company Calendar Today10/29/2026Last Earnings10/29/2026Next Earnings (Estimated)10/29/2026Corporate presentation10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PHAT's financial health is in the Red zone, according to TradeSmith. PHAT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PHAT CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees371Year Founded2018Price Target and Rating Average Price Target for Phathom Pharmaceuticals$20.11 High Price Target$28.00 Low Price Target$10.00 Potential Upside/Downside+223.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$221.25 million Net Margins-41.34% Pretax Margin-41.34% Return on EquityN/A Return on Assets-20.81% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.87 Sales & Book Value Annual Sales$175.11 million Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value($6.14) per share Price / Book-1.01Miscellaneous Outstanding Shares80,900,000Free Float73,353,000Market Cap$503.20 million OptionableOptionable Beta0.50 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PHAT) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredDO YOU LIVE HERE? ⬇️Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
